Navigating the Future of AMR: Insights and Innovations in Clinical Development

Join us for an insightful webinar on antimicrobial resistance (AMR), tailored for experts in clinical development.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/future-of-amr

Event overview

Join us for an insightful webinar on antimicrobial resistance (AMR), tailored for experts in clinical development. We’ll kick off with an introduction to AMR, setting the stage for a deeper understanding of this critical issue. Following this, a summary of key highlights from the September 26 high-level meeting at the United Nations on AMR will be provided, offering a sneak peek into the latest developments and discussions in the field.

The session will culminate in a dynamic panel discussion, featuring leading voices from scientific and regulatory backgrounds. Experts will delve into the challenges faced in clinical research and explore innovative ways to advance AMR. Don’t miss this opportunity to engage with thought leaders and gain valuable insights into the future of AMR solutions.


Learning Objectives

• Latest developments: Learn about the most recent advancements and discussions from the AMR meeting at the United Nations, providing insights into global efforts and strategies to combat AMR.
  
• Innovative approaches: Delve into innovative approaches and breakthroughs to advance scientific understanding.
  
• Future directions: Explore the challenges and opportunities in clinical research for AMR therapeutics, with expert perspectives on overcoming regulatory hurdles and ensuring compliance to drive progress.
  

Speakers:

Rachel Freeman
Principal – Antimicrobial Resistance, Global Public Health
IQVIA

Rachel Freeman is an infectious disease epidemiologist by training with over 15 years of experience working in the field of antimicrobial resistance (AMR). She has held positions across several sectors, including health care, academia, public health, and industry. Freeman is passionate about incorporating data into solutions designed to tackle AMR and has spent the majority of her career implementing surveillance systems and optimizing data collection. Freeman is leading IQVIA’s AMR strategy, including the development of innovative solutions and offerings that integrate real-world data into decision-making. She is an advocate for the need for cross-sectoral and transdisciplinary work in addressing the threat posed by AMR and is leading engagements with national bodies and the life sciences industry in support of generating valuable data assets that may be used to provide powerful insights.


Sharon Hughes
Senior Therapeutic Strategy Director, Infectious Diseases and Vaccines
IQVIA

Sharon Hughes is a senior director of therapeutic strategy in infectious diseases and vaccines, with over 29 years of industry experience spanning both clinical research and R&D formulations. She has a deep focus on respiratory infectious diseases, specifically on community-acquired and ventilator-acquired pneumonias, as well as studies involving antimicrobial resistance and invasive fungal infections in vulnerable HSCT and immunocompromised populations. She has over a decade of experience managing clinical trials and developing therapeutic strategies around VABP/HABP/CABP and VRE/CRE-related infection protocols.

Erin Duffy
Chief of Research and Development
CARB-X

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/future-of-amr